Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7NVjEbZZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vCZ2lEPTB;MD6wPFI{OSBizszNNYLJZ2RnW0GQR1XS
SW756MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDD[mhRUUN3ME2wMlE1ODJ2IDFOwG0>MmTwV2FPT0WU
CTV-1NYrmOYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGL1NIpKSzVyPUCuNVY{QThiIN88US=>NVrVPFY1W0GQR1XS
HSC-4MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTBwMUexOVghKM7:TR?=M3LqfHNCVkeHUh?=
LAMA-84NF:3ZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTBwMki2OlQhKM7:TR?=Ml3CV2FPT0WU
KU812Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwM{SwOlghKM7:TR?=MVvTRW5ITVJ?
HCC1806NH3rVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHMN4VKSzVyPUCuN|UzOTZiIN88US=>MXrTRW5ITVJ?
DOKNYn0WmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX5bIFKSzVyPUCuN|c4QDZiIN88US=>NX\aRoJkW0GQR1XS
NCI-H209NUfkNmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrTTWM2OD1yLkSwPFA5KCEQvF2=NHjoOm5USU6JRWK=
EoL-1-cellM3fZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zKbWlEPTB;MD60NVU4PiBizszNNG\2bWVUSU6JRWK=
H9NXrte5hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33Gb2lEPTB;MD60N|Q3PCBizszNMYLTRW5ITVJ?
EM-2NGDES25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTBwNEO4PUAh|ryPMmXqV2FPT0WU
NCI-H292NWCxWZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHZTWM2OD1yLkS0NVA5KCEQvF2=NV\rWllOW0GQR1XS
697MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\4OWFKSzVyPUCuOFU3OzNiIN88US=>M3O3UnNCVkeHUh?=
BHT-101MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;SPVhXUUN3ME2wMlQ3PTliIN88US=>M2nwenNCVkeHUh?=
BE-13MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7YNFc6UUN3ME2wMlQ5PTd{IDFOwG0>M2O1O3NCVkeHUh?=
RS4-11NIXVXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HlOGlEPTB;MD60PFU5PCBizszNM2Pad3NCVkeHUh?=
IGROV-1M{joeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTBwNEi3PVchKM7:TR?=NGnDTphUSU6JRWK=
KE-37MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHKc5hlUUN3ME2wMlQ6PTB7IDFOwG0>MXXTRW5ITVJ?
BV-173MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETNU4ZKSzVyPUCuOVA4QTJiIN88US=>NY[4epJsW0GQR1XS
MEG-01NEjNRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTy[IRYUUN3ME2wMlUyOjF2IDFOwG0>MmjGV2FPT0WU
LB2241-RCCNGDabIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTBwNUO3NVghKM7:TR?=MVvTRW5ITVJ?
ACHNNXKxXWhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne1TWM2OD1yLkW0NFY6KCEQvF2=MUPTRW5ITVJ?
CTB-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTBwNUS4NkAh|ryPM3HBVHNCVkeHUh?=
HT-1080NELYNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTBwNUWzOFkhKM7:TR?=NI\vUZBUSU6JRWK=
CHL-1M4Lu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDSTWM2OD1yLkW1OFY2KCEQvF2=M1;6RXNCVkeHUh?=
EW-3NHXle2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwNUW5N|UhKM7:TR?=MkLnV2FPT0WU
ES1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTBwNke0PVghKM7:TR?=MUfTRW5ITVJ?
KASUMI-1M3fVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTzTWM2OD1yLkeyN|MhKM7:TR?=MXHTRW5ITVJ?
SW13MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHyTWM2OD1yLkezO|k5KCEQvF2=MkfIV2FPT0WU
A3-KAWMnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\uTWM2OD1yLke5NlA5KCEQvF2=MWrTRW5ITVJ?
LB771-HNCNXvvR3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTBwOEOxNFQhKM7:TR?=M2PIO3NCVkeHUh?=
OC-314NXzFXWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIizeJZKSzVyPUCuPFY6PjViIN88US=>Ml3tV2FPT0WU
MLMAMl3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HCPGlEPTB;MD65NFY4PSBizszNNYfvUY5SW0GQR1XS
KARPAS-45NVXqfXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXxVnFKSzVyPUCuPVI1PjZiIN88US=>NH\VflFUSU6JRWK=
CAL-27MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrY[Y9KSzVyPUCuPVI6ODZiIN88US=>Ml:4V2FPT0WU
SK-NEP-1NWniUVdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{SxR2lEPTB;MD65O|I1QCBizszNMnX0V2FPT0WU
COR-L105NYPrOFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjldGtKSzVyPUGuNFA{QTRiIN88US=>NWTFPGh5W0GQR1XS
TI-73NUfXTXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTFwMEG2OUAh|ryPNW\Md5lRW0GQR1XS
JVM-3MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwMEWwNVchKM7:TR?=NXGxN4diW0GQR1XS
HAL-01NHroS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HuZ2lEPTB;MT6wPFgyKCEQvF2=NXHPU3ZQW0GQR1XS
QIMR-WILNUjBN2I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XYeWlEPTB;MT6wPVA2QCBizszNMnS2V2FPT0WU
HSC-3NE[4NY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnvboxKSzVyPUGuNVE4QDNiIN88US=>NVPiXG57W0GQR1XS
KY821MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnKSo5KSzVyPUGuNVM{PTFiIN88US=>M{O4[XNCVkeHUh?=
5637M{D4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTFwMUO4NFMhKM7:TR?=NWrUZ2VsW0GQR1XS
CAL-33NXSwXFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDKTWM2OD1zLkG5N|AzKCEQvF2=NH;qUWxUSU6JRWK=
ES4NYrx[41jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELCT|ZKSzVyPUGuNlA4QSBizszNMYrTRW5ITVJ?
BHYM{TBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTFwMkK4PVIhKM7:TR?=Ml34V2FPT0WU
LB1047-RCCMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[xTWM2OD1zLkKzO|g2KCEQvF2=NEnKUZdUSU6JRWK=
H4MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIq2bFZKSzVyPUGuNlQzPTViIN88US=>MXLTRW5ITVJ?
RPMI-8866NIrlRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPxPXRJUUN3ME2xMlI3OTB4IDFOwG0>Mm\0V2FPT0WU
HO-1-N-1M17OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknoTWM2OD1zLkK2N|Y6KCEQvF2=MVjTRW5ITVJ?
BB30-HNCM4L5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XUcWlEPTB;MT6yPFcyPCBizszNMVHTRW5ITVJ?
PC-14MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[yZVJKSzVyPUGuNlkzODViIN88US=>NVi3XJlDW0GQR1XS
NUGC-3NXm0eXlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTFwMkmzOVYhKM7:TR?=MYHTRW5ITVJ?
A4-FukMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfiTWM2OD1zLkOwO|A1KCEQvF2=NUHMRXdwW0GQR1XS
MHH-NB-11MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzVTWM2OD1zLkOxN|g{KCEQvF2=NYHCe4s1W0GQR1XS
KOSC-2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmr4TWM2OD1zLkOxO|c2KCEQvF2=NIjUNphUSU6JRWK=
A498NF3QSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkf0TWM2OD1zLkSwNVE{KCEQvF2=MXfTRW5ITVJ?
KG-1NHHsfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TkU2lEPTB;MT60NVI4OyBizszNM{jWXXNCVkeHUh?=
DELMke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nmT2lEPTB;MT60N|Y2PyBizszNMX7TRW5ITVJ?
EW-16M1ntZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoKzTWM2OD1zLkSzPVc{KCEQvF2=MnHuV2FPT0WU
BPH-1NUnjNpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHNOZFKSzVyPUGuOFQ5ODViIN88US=>NGXlfm1USU6JRWK=
JARNVXI[3pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjR[G5KSzVyPUGuOFk{PiBizszNMUHTRW5ITVJ?
J-RT3-T3-5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDGTWM2OD1zLkWxO|IzKCEQvF2=M1\oeXNCVkeHUh?=
A375MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTFwNUG3O|IhKM7:TR?=MXLTRW5ITVJ?
SW954MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7DTWM2OD1zLkW1NFA4KCEQvF2=MV3TRW5ITVJ?
Ca9-22NYLrR|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HUTGlEPTB;MT61OlI3KCEQvF2=M1rM[XNCVkeHUh?=
D-566MGMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFO3d2NKSzVyPUGuOVcyPTViIN88US=>M4HFU3NCVkeHUh?=
SCC-15NFSwUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrIVWRKSzVyPUGuOlE5ODRiIN88US=>M4fEdHNCVkeHUh?=
HD-MY-ZNEe1W|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXlTWM2OD1zLk[zOVg1KCEQvF2=NV\LNI06W0GQR1XS
HT-1376MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFwNkSzOkAh|ryPMV;TRW5ITVJ?
CAL-54MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[4XpFKSzVyPUGuOlU4ODliIN88US=>NFnlTnFUSU6JRWK=
ONS-76MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVe2dXhEUUN3ME2xMlY4PTVzIDFOwG0>M2HHSHNCVkeHUh?=
EFO-27MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DvdWlEPTB;MT62PFkzKCEQvF2=MUPTRW5ITVJ?
769-PM4nxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGr3fodKSzVyPUGuOlk2QTZiIN88US=>M{[zbHNCVkeHUh?=
MV-4-11Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHveXA4UUN3ME2xMlY6QDV4IDFOwG0>NIfPbplUSU6JRWK=
NKM-1NGD0V5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXkfYRKSzVyPUGuO|E5ODJiIN88US=>MYfTRW5ITVJ?
LOXIMVINVzvTmM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPzZ2ZKSzVyPUGuO|Q2QTliIN88US=>NHP6eZVUSU6JRWK=
KYSE-140Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFwN{W2OVUhKM7:TR?=NH:zXWJUSU6JRWK=
ES5M1\YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEm4dVZKSzVyPUGuPFY4PDdiIN88US=>NYD4fGdSW0GQR1XS
BB65-RCCMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\GWVN5UUN3ME2xMlg6QDR7IDFOwG0>Mn3zV2FPT0WU
HNMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrKZXh1UUN3ME2xMlg6QDd2IDFOwG0>M3O1eHNCVkeHUh?=
A101DNYH3c4MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rES2lEPTB;MT65N|YzQCBizszNMkDaV2FPT0WU
LoVoMlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVn2OndvUUN3ME2xMlk4Pjd7IDFOwG0>NU\rNWhXW0GQR1XS
NCI-H526MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LIOGlEPTB;MT65PVMzPSBizszNNVLiSXhTW0GQR1XS
NCI-H1693MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXmwe|FJUUN3ME2xMlk6QDh6IDFOwG0>M{L5eXNCVkeHUh?=
OVCAR-4NIfvU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJwMEC0N|UhKM7:TR?=NIDQ[WtUSU6JRWK=
SK-HEP-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PzZmlEPTB;Mj6wNFc1PSBizszNMVPTRW5ITVJ?
C2BBe1MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjX[FJKSzVyPUKuNFM{PzJiIN88US=>MX7TRW5ITVJ?
MEL-JUSOMnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIixVHBKSzVyPUKuNFQ1PjRiIN88US=>M4PjT3NCVkeHUh?=
MOLT-16M4\lNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXqcmRJUUN3ME2yMlA4ODV6IDFOwG0>MkH5V2FPT0WU
NBsusSRMlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HMV2lEPTB;Mj6wPVg5QSBizszNNFzmcGZUSU6JRWK=
TK10NFj5U5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTJwMUO0OVghKM7:TR?=M3XRbHNCVkeHUh?=
CAL-39MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXOTGRqUUN3ME2yMlE1PDhiIN88US=>MVzTRW5ITVJ?
NCI-H2030MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYK4XZFRUUN3ME2yMlE5QTd|IDFOwG0>Mlu1V2FPT0WU
HCT-116NWXkXIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjtfVVPUUN3ME2yMlIzQTh2IDFOwG0>M{m2T3NCVkeHUh?=
HTC-C3MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPETWM2OD1{LkK2PFI1KCEQvF2=M{LQc3NCVkeHUh?=
TYK-nuNE\PdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zsPWlEPTB;Mj6zNFkxQSBizszNM13yT3NCVkeHUh?=
FADUNYL2Z295T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvnTWM2OD1{LkOyNlk3KCEQvF2=NIjOeIZUSU6JRWK=
A431M3fpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvDSXRiUUN3ME2yMlM4ODJ3IDFOwG0>M1K5NXNCVkeHUh?=
TE-11M3rpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTJwM{iwNVkhKM7:TR?=M4jwV3NCVkeHUh?=
CAL-12TM1P0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUD0cY5HUUN3ME2yMlQxPDF5IDFOwG0>NEfkSYZUSU6JRWK=
DBMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDaU2pXUUN3ME2yMlQzQDZ7IDFOwG0>NVGwTIs4W0GQR1XS
L-363M1i1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTJwNEO1NFchKM7:TR?=MnHGV2FPT0WU
MSTO-211HMmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTJwNk[zPVEhKM7:TR?=M2LvZ3NCVkeHUh?=
SK-UT-1NIXh[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG[5N3hKSzVyPUKuO|E1ODZiIN88US=>M2C2UXNCVkeHUh?=
RPMI-8226MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH32WJdKSzVyPUKuO|MyPjRiIN88US=>NHXpc|NUSU6JRWK=
SF295M4fvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTJwN{SzNUAh|ryPNGDiW|NUSU6JRWK=
OS-RC-2NFHDZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTJwN{[2O|MhKM7:TR?=M{[4XXNCVkeHUh?=
SK-MEL-24MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\PTWM2OD1{Lke4NlI1KCEQvF2=Ml3OV2FPT0WU
COR-L23MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mme3TWM2OD1{Lke5OFY1KCEQvF2=M3z3Z3NCVkeHUh?=
MHH-PREB-1MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTJwOECxOlEhKM7:TR?=MUDTRW5ITVJ?
SK-N-DZMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJwOEG2N|ghKM7:TR?=M3zTcnNCVkeHUh?=
OMC-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTJwOEWwNFMhKM7:TR?=NXXu[5o{W0GQR1XS
SK-MEL-2NWfveWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUP2UnpnUUN3ME2yMlg6OjR|IDFOwG0>NGDyWlZUSU6JRWK=
SASMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJwOUm0NVUhKM7:TR?=M3n6WnNCVkeHUh?=
EPLC-272HM4TJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILMVYZKSzVyPUOuNFAzOzViIN88US=>MX7TRW5ITVJ?
8505CM2DCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHf6cphKSzVyPUOuNVA{ODFiIN88US=>MVHTRW5ITVJ?
EW-11NUjITpF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PzU2lEPTB;Mz6xOFI4PyBizszNMV3TRW5ITVJ?
YKG-1NVL4NG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXYTWM2OD1|LkG0O|A3KCEQvF2=NFzrOWxUSU6JRWK=
EC-GI-10NWO5TmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LXUmlEPTB;Mz6xO|I3OyBizszNNGH6SWtUSU6JRWK=
SK-LU-1NVLDXWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTNwMUi0NVghKM7:TR?=M4HOXXNCVkeHUh?=
P30-OHKNYjrUmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnsc2RKSzVyPUOuNlAyOTdiIN88US=>NUfCSoE2W0GQR1XS
T-24NF\JVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGm1R2dKSzVyPUOuNlE5OTRiIN88US=>NYrueXdNW0GQR1XS
HSC-2NU\xW20{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzlTWM2OD1|LkKyNlMzKCEQvF2=MWrTRW5ITVJ?
SK-MES-1M1[wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfEdHNDUUN3ME2zMlI1QDJ7IDFOwG0>M1fKdXNCVkeHUh?=
SW48NE\rcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\ybFJwUUN3ME2zMlI2PDh4IDFOwG0>M3nWVnNCVkeHUh?=
ME-180NUny[4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\FbmlEPTB;Mz6yOlA2OSBizszNMl;XV2FPT0WU
NCI-H2009MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nL[2lEPTB;Mz6yPVAyKCEQvF2=NV3M[op3W0GQR1XS
HL-60MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlW3TWM2OD1|LkK5NVMhKM7:TR?=NXzlZVFYW0GQR1XS
NCI-N87MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PHPGlEPTB;Mz6zNFE4OiBizszNNVzLTHNmW0GQR1XS
GMS-10NXiwUpd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\wVohKSzVyPUOuN|QxQDZiIN88US=>MVLTRW5ITVJ?
SCHMn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTNwNEC4OFQhKM7:TR?=M1fBb3NCVkeHUh?=
C-33-ANHTaT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HyT2lEPTB;Mz60NVQzOSBizszNNIHYW3pUSU6JRWK=
NCI-H1703MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVS4RYNWUUN3ME2zMlQyQDF{IDFOwG0>MYfTRW5ITVJ?
A427MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrGfoR2UUN3ME2zMlQ3OTJ2IDFOwG0>NG\oUoRUSU6JRWK=
MOLT-4NH7zUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPmNVN1UUN3ME2zMlQ5OTl7IDFOwG0>NUHQb|h[W0GQR1XS
NCI-H1792MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV6wVJJIUUN3ME2zMlQ6QDB{IDFOwG0>M375ZXNCVkeHUh?=
NCI-H1650M4Swc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfiWGJKSzVyPUOuOVczQSBizszNM4P2VnNCVkeHUh?=
H-EMC-SSMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XHZWlEPTB;Mz61PFU3QSBizszNM1Lp[nNCVkeHUh?=
SW982NGDmNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTNwNUi4NlkhKM7:TR?=M1LrW3NCVkeHUh?=
DSH1NWLWWnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPJc5RKSzVyPUOuOlQyOjJiIN88US=>MW\TRW5ITVJ?
NOS-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3HZYlCUUN3ME2zMlY1Ojd4IDFOwG0>NH7pcpFUSU6JRWK=
BT-549NXXINnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfreGtKSzVyPUOuOlc5PTRiIN88US=>Mn3xV2FPT0WU
HuCCT1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDWcVNKSzVyPUOuO|QyPzdiIN88US=>NHjTWIVUSU6JRWK=
NCI-H1755NIriZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrzTWM2OD1|Lkm2PVcyKCEQvF2=MXzTRW5ITVJ?
KYSE-450MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HReGlEPTB;Mz65Olk6PyBizszNMmL5V2FPT0WU
MIA-PaCa-2M4PKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfjVlhpUUN3ME2zMlk4OjliIN88US=>MX7TRW5ITVJ?
U-266NGDIRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XseGlEPTB;Mz65O|Q5OSBizszNMl7GV2FPT0WU
MewoM2LpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULWW3J1UUN3ME20MlA3OzZzIDFOwG0>M3LEVXNCVkeHUh?=
KYSE-520NWOzOW9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTRwMEm3PVkhKM7:TR?=NGLL[4xUSU6JRWK=
MN-60M37mbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHuTWM2OD12LkGwOVAyKCEQvF2=M4fFVXNCVkeHUh?=
Ramos-2G6-4C10M3O5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3Vem56UUN3ME20MlE3PzN7IDFOwG0>MWDTRW5ITVJ?
SK-MEL-1MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jUNGlEPTB;ND6xPFY6PSBizszNM{jtPXNCVkeHUh?=
ABC-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDzTWM2OD12LkKzN|M{KCEQvF2=MlP6V2FPT0WU
CAKI-1M1fSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTRwMkS1O|EhKM7:TR?=M4[0TnNCVkeHUh?=
HOSMkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTRwMkmxOFEhKM7:TR?=M4\hU3NCVkeHUh?=
SN12CM1HJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLqd2M3UUN3ME20MlM1OjR2IDFOwG0>NFexXWxUSU6JRWK=
NB13NGDvcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVu0S|lSUUN3ME20MlM4OzV3IDFOwG0>MoroV2FPT0WU
M14MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXUTWM2OD12LkS4O|kzKCEQvF2=M1W3RXNCVkeHUh?=
GP5dNHSxfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\UWm1mUUN3ME20MlUxOTJiIN88US=>M1zzbnNCVkeHUh?=
NCI-H720MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nCR2lEPTB;ND61N|YyOiBizszNNWnXOY1tW0GQR1XS
D-423MGNWTJOW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTRwNUO5NlQhKM7:TR?=NXrr[G5PW0GQR1XS
ChaGo-K-1NUn5VZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT6bmVKSzVyPUSuOVk2PTliIN88US=>NVP3SIpuW0GQR1XS
MEL-HONFKyepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGj1UGVKSzVyPUSuOlEzPjFiIN88US=>NEfHRmRUSU6JRWK=
MHH-ES-1NWnYdWlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTRwNkK0NVEhKM7:TR?=M2\EXHNCVkeHUh?=
KYSE-270M3XCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnuTWM2OD12Lk[1NVI3KCEQvF2=NV;VVW15W0GQR1XS
GI-ME-NM1XQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVmyRVhtUUN3ME20MlcyOjlzIDFOwG0>MW\TRW5ITVJ?
HOP-92MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fOU2lEPTB;ND64NVM4QSBizszNNX7rRlRbW0GQR1XS
MKN1NGDtfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjpXVBWUUN3ME20Mlg{QTF2IDFOwG0>M2i4SXNCVkeHUh?=
ML-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFKzXpNKSzVyPUSuPFU3OjZiIN88US=>MkPBV2FPT0WU
RO82-W-1M4nXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTRwOUK5PEAh|ryPNGSzXoNUSU6JRWK=
G-361Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzCXpRKSzVyPUWuNFExODNiIN88US=>MmT4V2FPT0WU
HC-1MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGj6T3lKSzVyPUWuNFMzQTFiIN88US=>NFu3UXlUSU6JRWK=
EW-24MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHqWoFkUUN3ME21MlA1ODN6IDFOwG0>M1vMOXNCVkeHUh?=
HuP-T4NF6zSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTVwMUSzN|QhKM7:TR?=M1PRTHNCVkeHUh?=
8-MG-BAM1vUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTMcFJJUUN3ME21MlM1OjhiIN88US=>NHHMXGpUSU6JRWK=
HGC-27NEHZT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HRZ2lEPTB;NT6zO|Y5OiBizszNMkT3V2FPT0WU
TE-12NEPRVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjCUIhKSzVyPUWuOFE2QDViIN88US=>Mny5V2FPT0WU
GT3TKBM4j3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXSTWM2OD13LkS0NlEzKCEQvF2=M37KcHNCVkeHUh?=
DOHH-2MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nafWlEPTB;NT60OVk5PiBizszNM12zfnNCVkeHUh?=
Ca-SkiM3vNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jP[GlEPTB;NT60OlEyPSBizszNNYTsTHZxW0GQR1XS
A172MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nJT2lEPTB;NT61OFkzPSBizszNMoC1V2FPT0WU
EGI-1M2mwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjvOok1UUN3ME21MlU5QTN6IDFOwG0>NEG4WIdUSU6JRWK=
MZ2-MELMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17XdGlEPTB;NT62NVQ5PiBizszNNHjGR2dUSU6JRWK=
SW1710MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLCTWM2OD13Lk[5NFkyKCEQvF2=M2\odnNCVkeHUh?=
HT-144M1vtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37BSGlEPTB;NT63NlY5PSBizszNNHnPcmFUSU6JRWK=
PA-1NImzbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXmTWM2OD13LkixPFk{KCEQvF2=MnnHV2FPT0WU
HCC1937M4rXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\uTmlEPTB;NT64N|kzQSBizszNNVvQdVZoW0GQR1XS
SK-OV-3NUjzcYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofXTWM2OD13LkmxNVIyKCEQvF2=NVO5cWJJW0GQR1XS
K5MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPxW2FwUUN3ME22MlA2OTdiIN88US=>M{DUT3NCVkeHUh?=
NMC-G1MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXizUFVDUUN3ME22MlA4Pzl5IDFOwG0>M33VN3NCVkeHUh?=
MDA-MB-361MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PQdGlEPTB;Nj6wPVI3OSBizszNMofrV2FPT0WU
EKVXMonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTZwMUO1NFEhKM7:TR?=MVTTRW5ITVJ?
ES7MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXzVXBGUUN3ME22MlE3OTF3IDFOwG0>M{LqdXNCVkeHUh?=
KS-1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGq4N3RKSzVyPU[uNVc6QTNiIN88US=>NGryZm5USU6JRWK=
NCI-H661M3[wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3qzU2lEPTB;Nj6xPFA5OSBizszNNXj5eHBYW0GQR1XS
ES8Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLZTWM2OD14LkG4NFgzKCEQvF2=M3HvXHNCVkeHUh?=
NCI-H23M{nLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnGTZBiUUN3ME22MlIyQDF4IDFOwG0>M{\tNnNCVkeHUh?=
T47DM{fCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTZwMk[0OVchKM7:TR?=MmDSV2FPT0WU
A2780Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XnWmlEPTB;Nj6zO|cxOSBizszNM3zVZnNCVkeHUh?=
SCC-4NETqWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTZwNEO1OlEhKM7:TR?=NYT4dlk5W0GQR1XS
VA-ES-BJMkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHzTWM2OD14Lkm3NFQ{KCEQvF2=MYLTRW5ITVJ?
no-11M4\hTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHI[VNFUUN3ME23MlE3PDFiIN88US=>NWO5Nm8zW0GQR1XS
KU-19-19MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;sTWM2OD15LkG2OFc3KCEQvF2=M3O1O3NCVkeHUh?=
MKN45MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXu2XW5rUUN3ME23MlE5Pjl7IDFOwG0>MYnTRW5ITVJ?
SCC-25M1G5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTdwMkO0NVQhKM7:TR?=M17BUXNCVkeHUh?=
ETK-1MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTdwMkW1NVQhKM7:TR?=NVzLZW1jW0GQR1XS
COR-L88MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXCTWM2OD15LkK5N|E6KCEQvF2=MkXPV2FPT0WU
8305CNVfoe3BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkD3TWM2OD15LkOyOFkzKCEQvF2=MkDhV2FPT0WU
Detroit562MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTdwM{K1NFYhKM7:TR?=M1\BVnNCVkeHUh?=
SNU-449M2XCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTdwM{e2OVEhKM7:TR?=MlPTV2FPT0WU
A704MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfBOm9KSzVyPUeuN|gzPzhiIN88US=>MVfTRW5ITVJ?
D-502MGNIfsNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTdwM{i0O|MhKM7:TR?=MnnyV2FPT0WU
NCI-H2228NYXS[IpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rVO2lEPTB;Nz60NVQ2QCBizszNNEXQUmNUSU6JRWK=
CHP-212M3fLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\yTWM2OD15LkWxPFk3KCEQvF2=M4Hy[nNCVkeHUh?=
VMRC-RCZNHHmO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfoN5Z4UUN3ME23MlU6ODZ4IDFOwG0>M2nmSHNCVkeHUh?=
RPMI-2650NEDZXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTdwN{CzNVIhKM7:TR?=M2TDfXNCVkeHUh?=
HCC2218MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTlTWM2OD15LkeyNlU5KCEQvF2=M2rLO3NCVkeHUh?=
GCTMmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD4TWM2OD15LkiyNVczKCEQvF2=M2n5U3NCVkeHUh?=
SW780M1HyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3sPYxHUUN3ME23Mlk6ODZiIN88US=>NFW5PGJUSU6JRWK=
KMOE-2MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XRPWlEPTB;OD6wOFA4KCEQvF2=NIjVdXVUSU6JRWK=
KYSE-180Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3ZW2RKSzVyPUiuNFg3PDhiIN88US=>NH\SXY9USU6JRWK=
TE-1MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjlTWM2OD16LkGxNFU4KCEQvF2=NYj6R4VoW0GQR1XS
OAW-42M2[1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojuTWM2OD16LkK1OFk3KCEQvF2=M4PvbXNCVkeHUh?=
VM-CUB-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRThwMkizOlQhKM7:TR?=M17odnNCVkeHUh?=
ECC10NEK1XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M161c2lEPTB;OD6yPFM6PyBizszNMWPTRW5ITVJ?
SW1573MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7SXJJxUUN3ME24MlQ1PDZ3IDFOwG0>M2HmSXNCVkeHUh?=
NCI-H1299MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3uRnd1UUN3ME24MlU6Pzd2IDFOwG0>Ml3hV2FPT0WU
ALL-POMkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXCTWM2OD16Lk[2OVk4KCEQvF2=M4nVbXNCVkeHUh?=
OVCAR-5M3S1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRThwN{e2NlUhKM7:TR?=MlH3V2FPT0WU
NCI-SNU-5NUPZN2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRThwOEOwNFEhKM7:TR?=NHLabnNUSU6JRWK=
NCI-H2342MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRThwOEOxNFEhKM7:TR?=MmS1V2FPT0WU
RPMI-7951NGTBdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGKyOmtKSzVyPUiuPFQyPTdiIN88US=>NFO4coFUSU6JRWK=
RCM-1NFW1fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXGxbXZQUUN3ME25MlA5OTR3IDFOwG0>NEjQUlFUSU6JRWK=
DaoyNWnnSIRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTlwMUKwNlghKM7:TR?=MXvTRW5ITVJ?
HCC1395NILhV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\1[4dYUUN3ME25MlMxQDl4IDFOwG0>NEjleINUSU6JRWK=
786-0Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\VTWM2OD17LkO2NFI3KCEQvF2=MXfTRW5ITVJ?
GAMGNHyxe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjP[plKSzVyPUmuOlU2OzRiIN88US=>M1ziNXNCVkeHUh?=
HCC1954NHjFVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\hXGF7UUN3ME25Mlg2QDV7IDFOwG0>NV\DT3IxW0GQR1XS
NCI-H1838MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXmTWM2OD17LkmwN|cyKCEQvF2=MXnTRW5ITVJ?
SW620MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fOV2lEPTB;OT65OVM2PyBizszNMWnTRW5ITVJ?
NCI-H358NF[4dVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3K0NGlEPTB;MUCuOFE6PyBizszNMVvTRW5ITVJ?
NCI-H1793MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGf3NVhKSzVyPUGwMlQzPDhiIN88US=>NGrrNHdUSU6JRWK=
NCI-H1666NXX5SZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PndWlEPTB;MUCuOFM2PSBizszNM3PRNHNCVkeHUh?=
MZ7-melMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvGRZR1UUN3ME2xNE41PzV|IDFOwG0>M3W0PHNCVkeHUh?=
MDA-MB-175-VIIMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnteYJKSzVyPUGwMlY{QTZiIN88US=>MoTlV2FPT0WU
COLO-829NWflc4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTFyLkiwNFQhKM7:TR?=NXjtfJZwW0GQR1XS
RVH-421MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk[zTWM2OD1zMT6xOVIhKM7:TR?=M1nQV3NCVkeHUh?=
A549M2T5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTFzLkK0O|ghKM7:TR?=MmjDV2FPT0WU
DJM-1NXvSV3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HWcmlEPTB;MUGuN|g{OyBizszNNECydJdUSU6JRWK=
IST-MEL1M3vpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInISG1KSzVyPUGxMlc{OTliIN88US=>NHP0NWNUSU6JRWK=
BENMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXj2cnBrUUN3ME2xNU44PDB{IDFOwG0>NXjwPXcxW0GQR1XS
KM12NFn4TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDUNZRKSzVyPUGxMlkxQTFiIN88US=>M37WXXNCVkeHUh?=
HuO9NWHVbo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jtSWlEPTB;MUKuNFY3PiBizszNNEjNUHhUSU6JRWK=
U-2-OSM2fJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zjWWlEPTB;MUKuNFg6OyBizszNMkW0V2FPT0WU
RH-1M3HpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHmSXZKSzVyPUGyMlQ1PzJiIN88US=>MWDTRW5ITVJ?
NCI-H1048NHvTZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHMeFJKSzVyPUGyMlU2ODZiIN88US=>M3z2VXNCVkeHUh?=
Mo-TNWmzXHliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVyzSGJSUUN3ME2xNk44OzB5IDFOwG0>NWjrT3JYW0GQR1XS
KYSE-150NVLzRXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTF{Lke0OVUhKM7:TR?=MkTFV2FPT0WU
A388MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3HTWM2OD1zMj63O|E{KCEQvF2=M1;vfXNCVkeHUh?=
NCI-SNU-1NFvQeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLrTWM2OD1zMj64NFQ3KCEQvF2=NFyxO3FUSU6JRWK=
HELMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkL2TWM2OD1zMj64NlEzKCEQvF2=NIDMfVZUSU6JRWK=
UM-UC-3Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDQOmxjUUN3ME2xNk45QDd2IDFOwG0>MWDTRW5ITVJ?
TGBC24TKBMlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;S[lRKSzVyPUGzMlAzPjdiIN88US=>M4XXbnNCVkeHUh?=
SW626Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTPTWM2OD1zMz6yOFg2KCEQvF2=Mlj5V2FPT0WU
ES6NXP4N3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjFTWM2OD1zMz6yOVEzKCEQvF2=MoKwV2FPT0WU
NCI-H2029M1Pzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPwTWM2OD1zMz64NVA5KCEQvF2=MoDTV2FPT0WU
RXF393MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPPcXZKSzVyPUGzMlk6OjdiIN88US=>MWDTRW5ITVJ?
HMV-IIM4\4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\qTWM2OD1zND6wO|ghKM7:TR?=MlyxV2FPT0WU
EW-22MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LGOGlEPTB;MUSuNVUxOiBizszNMk\IV2FPT0WU
AsPC-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrGToFKSzVyPUG0MlU3PCBizszNNUXBe|Y6W0GQR1XS
COLO-678NX;MNmVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGW3[IFKSzVyPUG0MlczPzFiIN88US=>MV7TRW5ITVJ?
HCT-15M{f1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDFTWM2OD1zND64PFU2KCEQvF2=NXjXZpJbW0GQR1XS
HCE-TM3jNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{ezZmlEPTB;MUSuPFg4PCBizszNMlTJV2FPT0WU
SF539M1rjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnztTWM2OD1zNT6wOlQ{KCEQvF2=MkHEV2FPT0WU
AU565MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonuTWM2OD1zNT6yNFk3KCEQvF2=MY\TRW5ITVJ?
JVM-2NEXVUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnMTWM2OD1zNT6yOlgyKCEQvF2=MVfTRW5ITVJ?
CaR-1MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF3LkS0NVIhKM7:TR?=MmHSV2FPT0WU
23132-87NXy4PI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jVcWlEPTB;MUWuPFQ6PSBizszNMVvTRW5ITVJ?
A673M2HKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTF3Lkm2N|YhKM7:TR?=NGrk[FBUSU6JRWK=
KYSE-410MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;ZR2pKSzVyPUG2MlAzQSBizszNMWXTRW5ITVJ?
TE-9MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTF4LkC2NkAh|ryPMW\TRW5ITVJ?
LU-139NXzVOWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXqwZotUUUN3ME2xOk4yQDJ|IDFOwG0>NXzhOpF4W0GQR1XS
GCIYNVPhVWpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnq5TWM2OD1zNj6xPVE3KCEQvF2=MoTUV2FPT0WU
JEG-3NWnyU4Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPHVYtMUUN3ME2xOk4zPSBizszNMlrTV2FPT0WU
RT-112NICwUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTF4LkSxOFMhKM7:TR?=NWnxZ2s5W0GQR1XS
COLO-680NM13z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPvTWM2OD1zNj61NVA5KCEQvF2=MUnTRW5ITVJ?
LU-134-AMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDBV5kxUUN3ME2xOk46QDl|IDFOwG0>M2LsbHNCVkeHUh?=
MFM-223MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfUcoJ[UUN3ME2xO{4yPTN3IDFOwG0>MlTuV2FPT0WU
SF126NXfNWlNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTF5LkG3NFEhKM7:TR?=MofIV2FPT0WU
NCI-H28MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTF5LkKwOlYhKM7:TR?=NIXTT4dUSU6JRWK=
BFTC-905NEjOTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF5LkS4N|IhKM7:TR?=MXnTRW5ITVJ?
SCC-9NHPqPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fBbWlEPTB;MUeuOlI5PSBizszNM1vBVHNCVkeHUh?=
KNS-62NH[4fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnxN2pKSzVyPUG3MlY3OjliIN88US=>M1TGRnNCVkeHUh?=
Hs-578-TMnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTF5LkixOFkhKM7:TR?=NX71NHZsW0GQR1XS
D-336MGM2LLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjRdHpKSzVyPUG3MlgzQTRiIN88US=>NH;HeHhUSU6JRWK=
NCI-H82M3vwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnKPIxKSzVyPUG4MlAyQDNiIN88US=>MoO2V2FPT0WU
EFM-19NEPuZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlW0TWM2OD1zOD6wOVc4KCEQvF2=NF3selZUSU6JRWK=
TGBC11TKBNHPJeItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3IPXM4UUN3ME2xPE4yODJzIDFOwG0>M{XNXnNCVkeHUh?=
HEC-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnwR|BKSzVyPUG4MlI6OThiIN88US=>MlfNV2FPT0WU
HuP-T3M3\qXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XpZ2lEPTB;MUiuOVkzQSBizszNNEnM[YVUSU6JRWK=
SF268M3\KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofITWM2OD1zOD62O|AzKCEQvF2=MVvTRW5ITVJ?
COLO-792M2exPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\vUldKSzVyPUG4Mlc6QTdiIN88US=>NEfJTFBUSU6JRWK=
HLEMmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTF6LkizN|EhKM7:TR?=NIXH[Y1USU6JRWK=
A204MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPSRlJiUUN3ME2xPE46OTZ2IDFOwG0>M2O3eXNCVkeHUh?=
CAL-72MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qxVmlEPTB;MUmuNFg4PyBizszNM3Hye3NCVkeHUh?=
U031Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PrN2lEPTB;MUmuOFkxQSBizszNM1vaZ3NCVkeHUh?=
FTC-133MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTF7LkmzNFQhKM7:TR?=NELGWmNUSU6JRWK=
SK-MEL-28NH;zXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;DfWlEPTB;MkCuN|c3OSBizszNNV\TOYdKW0GQR1XS
KGNMlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHFTWM2OD1{MD60Olk6KCEQvF2=NXOwZVZbW0GQR1XS
HCC2998M33jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnOTWM2OD1{MT6zPVI3KCEQvF2=NVnHfpVPW0GQR1XS
GOTONHzu[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzRflRHUUN3ME2yNU41QDViIN88US=>MVrTRW5ITVJ?
AGSMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn6yTWM2OD1{MT64OFUyKCEQvF2=MXPTRW5ITVJ?
EW-13MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJ{LkGwNlIhKM7:TR?=MX3TRW5ITVJ?
P12-ICHIKAWAMmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWewSY81UUN3ME2yNk4yPjB|IDFOwG0>MUnTRW5ITVJ?
NCI-H1395M1O0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HLZ2lEPTB;MkKuNlkxPyBizszNNFzidVRUSU6JRWK=
A2058NF36e|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rG[mlEPTB;MkKuOFM1KCEQvF2=NH;q[|ZUSU6JRWK=
SH-4NVHZOYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XoeGlEPTB;MkKuO|A1PSBizszNM4L6XXNCVkeHUh?=
DoTc2-4510MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHLPGFKSzVyPUKzMlY1PzJiIN88US=>NFHYT3pUSU6JRWK=
MMAC-SFMkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrUbGJpUUN3ME2yN{43QTFzIDFOwG0>NH\uSldUSU6JRWK=
NCI-H510AM3vabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTJ|Lke5N|khKM7:TR?=Ml3tV2FPT0WU
HDLM-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XiUWlEPTB;MkSuNVQ3KCEQvF2=NGi4bXBUSU6JRWK=
KINGS-1M3\sTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TkTGlEPTB;MkSuNlQzKCEQvF2=MWrTRW5ITVJ?
NCI-H1648NHTiR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJ2LkSwNlQhKM7:TR?=NV7jOVBWW0GQR1XS
HCC1187NFjpTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTJ3LkCyN|UhKM7:TR?=MUDTRW5ITVJ?
BALL-1NIPlUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfUcXJSUUN3ME2yOU4zODZ{IDFOwG0>NXzKVWN5W0GQR1XS
SBC-1Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDLR|RKSzVyPUK1MlI6QTNiIN88US=>NWruZW9vW0GQR1XS
BFTC-909MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTJ3LkO1OVEhKM7:TR?=MWnTRW5ITVJ?
MOLT-13MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXmzWW1EUUN3ME2yOU43PzR2IDFOwG0>Mom3V2FPT0WU
SW1990NIHQd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Xs[GlEPTB;MkWuPVY2PSBizszNMVLTRW5ITVJ?
DK-MGNX7xSFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJ4LkC0OFMhKM7:TR?=NHP1VZJUSU6JRWK=
TE-8M4C1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTJ4LkC2OlghKM7:TR?=NVnOdpJFW0GQR1XS
BeckerM2nNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LaWGlEPTB;Mk[uNVU4PCBizszNNX3GemNSW0GQR1XS
KYSE-70MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn:2TWM2OD1{Nj61N|E4KCEQvF2=M1zCVnNCVkeHUh?=
MKN7M1jqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1j2cGlEPTB;MkeuO|Q4QSBizszNMXTTRW5ITVJ?
D-392MGMme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYX5cXlHUUN3ME2yO{44Pjl2IDFOwG0>MljJV2FPT0WU
NH-12MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3q2UmlEPTB;MkiuNVIzQSBizszNNVvVdYhIW0GQR1XS
EW-18M3PCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjXNJQ{UUN3ME2yPE4zOjF6IDFOwG0>M3foVHNCVkeHUh?=
LCLC-97TM1NX;HPJc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJ6LkK3OlIhKM7:TR?=M3L2RXNCVkeHUh?=
NCI-H1770M3jzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PxVWlEPTB;MkiuN|U3PiBizszNNHm0OHpUSU6JRWK=
BT-20NVLGfotFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHvNpljUUN3ME2yPE4{Pjh3IDFOwG0>MV7TRW5ITVJ?
DBTRG-05MGNX3lUGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TzNWlEPTB;MkiuOFg{QCBizszNMYTTRW5ITVJ?
HPAF-IINWn2[WpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfLTWM2OD1{OD63O|khKM7:TR?=NF[2T4FUSU6JRWK=
SW837M1vpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{ewU2lEPTB;MkmuN|M5PSBizszNNFW0dXlUSU6JRWK=
647-VNUjmcZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjsVGlpUUN3ME2yPU44ODB|IDFOwG0>MnTVV2FPT0WU
J82NG[zPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJ7LkiwNVMhKM7:TR?=MUjTRW5ITVJ?
MC116MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTNyLkC3N|MhKM7:TR?=NVzpSYtEW0GQR1XS
NCI-H69MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2W3SWlEPTB;M{CuOlA6OyBizszNM2\GPHNCVkeHUh?=
NB6MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f1SmlEPTB;M{GuN|YzQSBizszNMm\JV2FPT0WU
CAL-120NUL3WZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfwXpQ{UUN3ME2zNk41OzF5IDFOwG0>MlO3V2FPT0WU
U-87-MGNY\KW205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrVSmRKSzVyPUOzMlAzPTFiIN88US=>MVvTRW5ITVJ?
NCI-H1304Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2m5emlEPTB;M{OuNFM2PCBizszNM1\4[XNCVkeHUh?=
YH-13MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTqTWM2OD1|Mz6yOVM2KCEQvF2=MYrTRW5ITVJ?
RMG-IMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTN|LkSyPFUhKM7:TR?=Mke1V2FPT0WU
LU-65MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml60TWM2OD1|ND6xOFA5KCEQvF2=MXzTRW5ITVJ?
GB-1M1nseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\vTWM2OD1|NT6wO|I6KCEQvF2=MnXKV2FPT0WU
DU-4475NGezNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\MTWM2OD1|NT6xOVU{KCEQvF2=MWrTRW5ITVJ?
SBC-5MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2CwUmlEPTB;M{[uOVkxOiBizszNMXXTRW5ITVJ?
OE33MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXHUHRKSzVyPUO3Mlc2PzdiIN88US=>MUjTRW5ITVJ?
C8166MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LjU2lEPTB;M{iuOVI3PyBizszNNIPmO3BUSU6JRWK=
COLO-684NWq3W3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe5N5dKSzVyPUO4Mlc1OjhiIN88US=>NYrnTndqW0GQR1XS
NCI-H1155MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLTTWM2OD1|OT6wOFcyKCEQvF2=M1;2OHNCVkeHUh?=
ATN-1MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmSxTWM2OD1|OT63O|kzKCEQvF2=M1PpUnNCVkeHUh?=
KARPAS-299M3rtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3e5eWlEPTB;M{muPFM6KCEQvF2=NEXseWJUSU6JRWK=
KNS-81-FDMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXjNWFKSzVyPUSwMlM3ODRiIN88US=>M3;JZnNCVkeHUh?=
NCI-H1563MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjm[4NKSzVyPUSxMlUxOzliIN88US=>NV7HRmFSW0GQR1XS
NB14Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTPdWNKSzVyPUSyMlczPjNiIN88US=>NIX2[ZpUSU6JRWK=
COLO-800NI\xVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPxNlU5UUN3ME20Nk45PTF5IDFOwG0>NIqzR|lUSU6JRWK=
MS-1NI\UOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHn6dmNKSzVyPUSzMlA1QDNiIN88US=>MULTRW5ITVJ?
OVCAR-8MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrje|JvUUN3ME20N{43QDB7IDFOwG0>MXjTRW5ITVJ?
SK-PN-DWM4SxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nreGlEPTB;NEOuPFc4PiBizszNMVfTRW5ITVJ?
G-402MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTR|LkmwNFYhKM7:TR?=NHzNfJVUSU6JRWK=
NCI-H2291NVO5cXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTR2LkiwNVchKM7:TR?=MXTTRW5ITVJ?
PC-3M{DPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fSXWlEPTB;NEWuPFAzOyBizszNNWH4fWtIW0GQR1XS
NCI-H1581M3HEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnrTWM2OD12NT65PFg6KCEQvF2=NXO4TFlxW0GQR1XS
SW1116NYW3WYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknpTWM2OD12Nz6wNVgzKCEQvF2=MVPTRW5ITVJ?
ZR-75-30NV;YVJM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPxdJZKSzVyPUS3MlAzOzliIN88US=>MkPaV2FPT0WU
OCI-AML2M{PlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTMT4FWUUN3ME20O{4xQTF6IDFOwG0>NW[4VoxUW0GQR1XS
MDA-MB-231MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTR5Lk[yOFkhKM7:TR?=NI\NVZZUSU6JRWK=
ES3NXL6THBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTR6LkO1NlkhKM7:TR?=NX[1OZQ{W0GQR1XS
NCI-H630MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XuNWlEPTB;NEmuNVc1OiBizszNNV7lSopsW0GQR1XS
OE19M3vLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLmVHRmUUN3ME20PU4zQTB{IDFOwG0>MkDnV2FPT0WU
NCI-H1573NXntb21DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTR7Lk[4OlEhKM7:TR?=M3TETHNCVkeHUh?=
EW-1NXr5bY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTR7LkmwPFQhKM7:TR?=MoDJV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02810990 Not yet recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto September 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Customer Product Validation(3)


Click to enlarge
Rating
Source J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Human endothelial cells
Concentrations 0-10 μM
Incubation Time 15-60 min
Results Figure C defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s). IC50s of bosutinib are 100 nM and 10 μM. we next assessed the abilities of bosutinib to block ANDV-induced permeability at its IC50s from 15 to 60 min after VEGF addition, we find that bosutinib inhibited ANDV-induced permeability up to 40 to 50% but only at IC50s of 10 μM(Figure D).

Click to enlarge
Rating
Source J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines Mouse sperm
Concentrations 0-50 μM
Incubation Time 60 min
Results In the case of SKI606, a sharp inhibitory effect was observed at 50 μM.

Click to enlarge
Rating
Source Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines sperm
Concentrations 50 μΜ
Incubation Time
Results PKA and tyrosine phosphorylation was rescue by Ser/Thr phosphatase inhibitors SKI-606 and SU6656.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us